Sinopharm WIBP COVID-19 vaccine explained

Type:vaccine
Target:SARS-CoV-2
Vaccine Type:inactivated
Legal Status:Full and emergency authorizations

Full list of Sinopharm WIBP authorizations

Routes Of Administration:Intramuscular
Atc Prefix:None
Drugbank:DB15862
Synonyms:Zhongkangkewei (Chinese: 众康可维)

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV,[1] [2] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[3] The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

Medical uses

The vaccine is given by intramuscular injection. The administered is 2 doses in 3 weeks.[4] [5] [6]

Efficacy

In May 2021, peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials.

Manufacturing

In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.[7]

History

In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BIBP)[8] and the Wuhan Institute of Biological Products (WIBP). Both vaccines are chemically-inactivated whole virus vaccines for COVID-19.

On August 13, 2020, the Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[9]

Clinical trials

In March 2021, Cayetano Heredia University running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy.[10]

Authorizations

On February 25, 2021, China approved the vaccine for general use.[11]

According to The New York Times, the vaccine is only approved for limited use in United Arab Emirates.[12] On August 19, 2021, the Philippines approved the vaccine for emergency use authorization.[13]

Notes and References

  1. Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine. 29 April 2021. Presentation. World Health Organization. 10 July 2021. PDF. Evaluated BBIBP-CorV & WIBP-CorV. 6.
  2. Hadj Hassine I . Covid-19 vaccines and variants of concern: A review . Reviews in Medical Virology . 32 . 4 . e2313 . July 2022 . 34755408 . 8646685 . 10.1002/rmv.2313 . 243939603 .
  3. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial . JAMA . 326 . 1 . 35–45 . July 2021 . 34037666 . 8156175 . 10.1001/jama.2021.8565 . free .
  4. China National Biotec Group Company Limited . 29 October 2020 . G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd. . Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above . ClinicalTrials.gov.
  5. Universidad Peruana Cayetano Heredia . 3 November 2020 . National University of San Marcos, Peru . Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru (Covid-Peru) . NCT04612972 . ClinicalTrials.gov.
  6. News: 25 February 2021 . Two Chinese-developed COVID-19 vaccines under review . National Medical Products Administration . 11 April 2021.
  7. Web site: Sinopharm's Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses. 2021-06-08. CNA. en. 2021-06-08. https://web.archive.org/web/20210608191550/https://www.channelnewsasia.com/news/business/sinopharm-s-wuhan-affiliate-boosts-covid-19-shot-annual-capacity-to-1-billion-doses-14924936. dead.
  8. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X . Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial . The Lancet. Infectious Diseases . 21 . 1 . 39–51 . January 2021 . 33069281 . 7561304 . 10.1016/s1473-3099(20)30831-8 .
  9. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X . Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials . JAMA . 324 . 10 . 951–960 . September 2020 . 32789505 . 7426884 . 10.1001/jama.2020.15543 . free .
  10. Web site: March 9, 2021. COMUNICADO A LA OPINIÓN PÚBLICA. Universidad Peruana Cayetano Heredia.
  11. News: 2021-02-25. China approves two more domestic COVID-19 vaccines for public use. en. Reuters. 2021-03-30.
  12. News: Zimmer C, Corum J, Wee SL . Coronavirus Vaccine Tracker . en-US . The New York Times . 10 June 2020 . 2021-03-30. 0362-4331.
  13. News: De Vera A . FDA grants EUA to COVID-19 vaccine Sinopharm manufactured by Wuhan affiliate . Manila Bulletin . August 25, 2021.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sinopharm WIBP COVID-19 vaccine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.